<DOC>
	<DOCNO>NCT00320450</DOCNO>
	<brief_summary>The purpose research find effective safe SB-681323 treatment RA add standard anti-rheumatic treatment .</brief_summary>
	<brief_title>SB-681323 In Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Females pregnant lactating . Must use define contraceptive method childbearing potential . BMI range : 18.535.0 kg/m2 . Diagnosis RA ( rheumatoid arthritis ) accord revised 1987 American College Rheumatology ( ACR ) criterion . If RAmedication use : DiseaseModifying AntiRheumatic Drug ( DMARDS ) must stable least 8 week first trial visit . If oral antiRA therapy use , must stable least 4 week first trial visit . If Methotrexate medication use RAtherapy , Folate supplement must take stable red cell folate level . Must give informed consent . Must abstain alcohol trial participation . Nonresponder biological RA treatment . Has positive alcohol screen . Any history liver disease . Positive Hepatitis B surface antigen Hepatitis C antibody result within 3 month screen . Have significant disease place subject unacceptable risk participant trial . Acute infection . History active tuberculosis . History repeat chronic infection . History malignancy . History HIV immunosuppressive disease . Participated clinical trial within last 3 month nonbiological therapy 6 month biological therapy . Uncontrolled diabetes psoriasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>SB-681323</keyword>
	<keyword>CRP</keyword>
	<keyword>Rheumatoid Arthritis SB-681323 CRP RA</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
</DOC>